Study Summary
This trial is testing a new drug, DA-1229, for patients with aortic valve disease. The study will last 104 weeks, and patients will be given the drug either once a day or as a placebo. The study will have 3 phases: Screening, Treatment, and Follow-Up.
- Calcific Aortic Valve Disease
- Aortic Valve Stenosis
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 14 Secondary · Reporting Duration: 104 weeks
Trial Safety
Safety Progress
Trial Design
3 Treatment Groups
DA-1229 5mg
1 of 3
DA-1229 10 mg
1 of 3
Placebo
1 of 3
Active Control
Non-Treatment Group
867 Total Participants · 3 Treatment Groups
Primary Treatment: DA-1229 5mg · Has Placebo Group · Phase 2 & 3
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
To your knowledge, are there other similar trials underway?
"As of now, 4 trials for DA-1229 10 mg are underway in 11 cities within 2 nations. The first ever trial for DA-1229 10 mg was in 2019. That year, the study - which was sponsored by Dong-A ST Co., Ltd. - had 225 individuals taking part. It completed its Phase 2 drug approval. In the two years since 2019, a total of 18,281 trials have been completed." - Anonymous Online Contributor
Are there precedents for giving DA-1229 10 mg to patients?
"As of now, 4 different clinical trials are studying the effects of DA-1229 10 mg. 1 of these trials is currently in Phase 3. Most of the research is taking place in Seoul, Gangwondo; however, there are a total of 19 sites running DA-1229 10 mg trials." - Anonymous Online Contributor